Chloroquine Population Pharmacokinetics in Pre and Post-partum Women
Status:
Completed
Trial end date:
2017-05-01
Target enrollment:
Participant gender:
Summary
For the treatment of P.vivax the standard treatment is chloroquine. There is a growing body
of evidence suggesting that pregnant women may require different doses of drugs, including
antimalarials due to the physiological changes of pregnancy. It is important that any drug
used in pregnant women it is given at the correct dose. The only way to evaluate this is by
pharmacokinetic studies. The investigators propose to evaluate the pharmacokinetics of
chloroquine when use to treat P.vivax in the 2nd or 3rd trimester of pregnancy. The same
evaluation in the same woman post-partum is required as a control.